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Summary We have examined the killing effect of 4-S-cysteaminylphenol (4-S-CAP), a newly synthesised
melanin precursor, on B16 melanoma cell lines possessing different melanin-producing activities and found it
to be particularly effective in heavily melanised melanoma cells, but less so in moderately melanised melanoma
cells, and having no effect on amelanotic melanoma cells and nonmelanoma cells. Thus, it was found that the
killing effect of 4-S-CAP is highly dependent upon the synthesis of melanin and tyrosinase in melanoma cells,
suggesting that 4-S-CAP may become toxic to melanoma cells only after oxidation by tyrosinase. The killing
activity of4-S-CAP also was found to be associated with a profound inhibition of the thymidine incorporation
in pigmented melanoma cells, as compared to the uridine and leucine incorporation. Further, the inhibition of
DNA synthesis was most pronounced in heavily melanised melanoma cells, less so in moderately melanised
melanoma cells, and not seen in amelanotic melanoma cells. As a possible mechanism that might account for
this action, it may be that 4-S-CAP is oxidised by tyrosinase to the o-quinone form via the catechol derivative
and that some of the quinones then conjugate with sulfhydryl enzymes including DNA polymerase, thus
exerting a killing activity for pigmented melanoma cells. Thus, 4-S-CAP appears to provide a new, effective
cytotoxic agent for rational chemotherapy of malignant melanomas.
Many attempts have been made to develop a rational chemo-
therapy for malignant melanomas by utilising one of the
unique biochemical properties of such melanomas, their
melanin synthesis (Pawelek, 1976). This consists of the con-
version of tyrosine to dopa and dopaquinone in the presence
of tyrosinase (EC 1.14.18.1). In a malignant melanoma, the
synthesis of melanin is highly elevated because of a marked
increase of tyrosinase activity (Pawelek et al., 1973; Pawelek,
1976). Previously, Wick et al. (1977, 1978) have shown that
catecholic compounds related to dopa and dopamine possess
significant antitumoral activities against melanomas in vitro
and in vivo. However, a major drawback in using catechols as
chemotherapeutic agents is that they also possess certain
degrees of systemic toxicity that may result from an autoox-
idation of the catechols and a concomitant production of
active oxygen species (Graham et al., 1978a). As a result,
some catechols exhibit less of an antimelanoma effect than
the corresponding phenols (Rosowsky et al., 1979; Wick et
al., 1980). Thus, a rational approach to overcome this
difficulty would seem to be to use phenolic compounds that
are the immediate precursors of catecholic compounds. Fur-
ther, the phenol could be hydroxylated by tyrosinase to form
catechols within the melanoma cells.
Therefore, in a search for more effective melanocytotoxic
agents, we have synthesised various phenolic compounds as
substrates for tyrosinase, and have demonstrated that, among
these synthetic compounds, 4-S-cysteaminylphenol (4-S-CAP)
possesses the most significant effect in inhibiting the growth
of melanomas in experimental mice (Miura et al., 1987).
Pursuing our quest further, in this report, we have evaluated
the killing effects of 4-S-CAP on B16 melanoma cell lines
possessing different melanin-producing activities, and have
examined its effects on the inhibition of macromolecule syn-
thesis and cell cycle progression, so as to clarify the
mechanism of its antimelanoma effects.
Materials and methods
Chemicals
The 4-S-CAP used was synthesised at the Fujita-Gakuen
Health University, Toyoake, Aichi, Japan, by one of the
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authors (Dr S. Ito), and the details of this chemical synthesis
have been reported previously (Miura et al., 1987). The drug
solution was freshly prepared in a Ham's F-10 medium
(Gibco, Grand Island, NY) just before use at the beginning
of each experiment.
Cells
Four sublines of B16-XI melanoma cells, maintained in our
laboratory, were used. The pigment-producing capability of
the four cell lines was characterised as being capable ofheavy
(B16-XID), moderate (Bl 6-XIT, B16-XIW), or no pigment
production (Bi6-XIA), and all were derived originally from
the B16-XI cell line (Oikawa et al., 1987). L929 mouse
fibroblast cells, CHO Chinese hamster ovary cells, and HeLa
S3 cells were gifts from Aichi Cancer Center Research Insti-
tute, Nagoya, Japan. These cell lines have been maintained in
the Ham's F-10 medium, supplemented with 10% calf serum
(Flow Laboratories, Rockville, MD), penicillin (100 U ml-'),
and streptomycin (100 ytg ml-'), and incubated in a humidi-
fied atmosphere of 95% air-5% CO2 at 37°C.
Clonogenic assay
Cells (2 x 105) were plated in 60 mm plastic dishes (tissue
culture Petri dish; Falcon plastics, Oxnard, CA). After a 48 h
incubation, the medium was replaced with a fresh culture
medium containing the desired concentrations of 4-S-CAP,
and the cell cultures incubated at 37°C for I h. After drug
exposure the medium was removed, and the cells were rinsed
twice with the F-10 medium. The cells then were trypsinised
and counted with a Model D Coulter Counter (Coulter
Electrics, Inc., Hialeah, FL). Next, an appropriate number of
cells were plated in duplicate 60 mm Petri dishes containing
5 ml of the complete medium and incubated at 37°C in an
atmosphere of 95% air-5% CO2 for 14 days. A colony
containing more than 50 cells was counted as a viable colony,
and the surviving fraction was calculated in reference to the
untreated controls. At least three replicated experiments were
conducted for each treatment. The plating efficiency in the
control cultures of each cell line was as follows: B16-XID,
77 ± 9%; B16-XIT, 84 ± 10%; B16-XIW, 78 ± 6%; B16-XIA,
74 8%; L929, 58 + 9%; CHO, 71 ±11%; and HeLa S3,
73 ± 7%. The Do., and D0.01 values were measured as being
the 4-S-CAP dose (tg ml-') required to reduce survival after
1 h exposure to 0.1 and 0.01, respectively.
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Incorporation oflabelledprecursors into macromolecules
The effect of 4-S-CAP on the macromolecular synthesis was
determined by a method similar to that used by Wick (1978).
Cells (1 x 105) were plated in multiwell tissue culture trays
(Linbro Plastics, Vineland, NJ). After a 48 h incubation,
exponentially-growing cultures were aspirated and washed,
and 1 ml of a culture medium containing 2 gLCi ml1l amounts
of either 3H thymidine (specific activity, 2 Ci mmol-'),
5-3H uridine (specific activity, 25 Ci mmol-') or 3H leucine
(specific activity, 41 Ci mmol ') (New England Nuclear,
Boston, Mass.) and 4-S-CAP were added. After 1 h incu-
bation at 37'C, the medium was removed. Then, the cells
were washed once with phosphate buffered saline (PBS,
pH 7.2), and 1 ml of 10% trichloroacetic acid was added.
The resulting precipitate was washed three times with PBS,
after which 0.5 ml of I N KOH was added. After digestion at
37°C for 4 h, a portion was added to a scintillation fluid
(Aquasol-II; New England Nuclear) and then counted with a
Packard Tri-Carb 460CD liquid scintillation spectrometer
(Packard Instrument Co., Downers Grove, Ill). Values are
expressed as a percentage of inhibition, as compared to the
controls, and represent a mean ± s.d. of three separate
experiments.
Cell kinetics study
The cell cycle distribution of the melanoma cells treated with
4-S-CAP was determined from DNA histograms measured
by flow cytometry. Exponentially-growing cells were incu-
bated with different concentrations of 4-S-CAP at 37'C for
I h, after which the 4-S-CAP was removed by changing the
culture medium. After a 24 h incubation, the cells were tryp-
sinised from the dish and washed twice with PBS. The cells
then were stained with a mixture of propidium iodide (50 pg
ml-'; Calbiochem, San Diego, CA), RNAase (100Iggml-;
RNAase A, 4396 U mg-1, Worthington Biochemical Corp,
Freehold, NJ), and Triton-X-100 (0.2%) in PBS for 10min
(Taylor, 1980). The DNA count was assayed by flow cyto-
metry, using a FACScan (Becton-Dickinson, Sunnyvale,
CA), with a collection of fluorescence emissions longer than
590 nm. One x I05 cells were counted and the distribution
histograms of the fluorescence intensity in linear scale were
obtained. The cell cycle analysis by DNA distribution was
performed by using the 'CCANA 1' program reported by
Dean (1980), and the populations during the GI, S, and
G2-M phases were calculated. Each data value given repre-
sents a mean ± s.d. of three separate experiments. The same
experiments and subsequent analyses were done for the un-
treated controls.
Results
Killing effects of4-S-CAP
The dose-response survival curves of the four B16-XI mela-
noma cell lines after I h treatment with 4-S-CAP are shown
in Figure 1, and the Do., and D0.0, values of the 4-S-CAP for
each cell line are summarised in Table I. It was found that
4-S-CAP demonstrated a remarkably potent killing effect on
the heavily melanised B16-XID melanoma cells, and that the
Do., and D001 values were 7.7 ± 2.7 gg ml-' and 15.5 ± 3.7
gg ml-', respectively. In contrast, the same treatment with
4-S-CAP resulted in no significant killing effect on the
completely amelanotic B 16-XIA melanoma cells up to the
concentration of 500 gig ml-'. Similarly, 4-S-CAP had no
significant killing effect on three nonmelanoma cell lines
(L929, CHO, and HeLa S3) up to the concentration of
500 gml-'. With regard to the moderately melanised B16-
XIT and B16-XIW melanoma cells, 4-S-CAP showed a midd-
ling potency, an intermediate killing effect that fell between
the response seen in the heavily melanised cells and the lack
of a response in the amelanotic and nonmelanoma cells. The
Do., and D0.0, values were 60.2 ± 4.1 ;xg ml-' and 124.0 ±
0.1
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Figure 1 The survival curves of B16-XID (0), B16-XIT (A),
B16-XIW (A), and B16-XIA (0) melanoma cell lines after I h
treatment with 4-S-CAP. Two x 105 cells were inoculated into
60mm Falcon Petri dishes and incubated for 48 h. Cells were
incubated with different concentrations of 4-S-CAP at 37°C for
1 h. Survival was measured by colony formation. Values repre-
sent a mean ofthree to five experiments performed with duplicate
cultures; bars, s.d.
17.1 gigml-' for the B16-XIT cells, and 95.3 ± 8.3 fig ml
and 240.3 12.1 gig ml-' for the B16-XIW melanoma cells,
respectively. There were significant statistical differences in
both the Do., and D0.01 values of 4-S-CAP among the heavily
melanised, moderately melanised, and amelanotic cell lines
(P<0.01, by Student's t-test).
Inhibition ofDNA, RNA, andprotein synthesis
Figure 2 outlines the results of the effects of 4-S-CAP upon
the radiolabelled thymidine incorporation by the B16-XID,
B16-XIT, and B16-XIA melanom cells. Following a 1 h
exposure, the inhibition of thymidine incorporation was
found to be the most prominent in the heavily melanised
B16-XID melanoma cells and the percent of inhibition at
10 g ml-' was 92.1 ± 3.0%. On the other hand, the same
Table I Effects of 4-S-CAP on the cell survival in the B16-XI
melanoma cell lines and nonmelanoma cell lines
Cell lines Do., (pgmlI)a D001 (ggml-I)b
Melanoma
B16-XID 7.7± 2.7c,d 15.5±3.7d
B16-XIT 60.2±4.1e 124.0±17.1e
B16-XIW 95.3±8.3' 240.3+12.le
B16-XIA > 500 > 500
Nonmelanoma
L929 > 500 > 500
CHO >500 > 500
HeLa S3 > 500 > 500
aDose of4-S-CAP required to reduce cell survival after 1 h exposure
to 0.1; bDose of 4-S-CAP required to reduce cell survival after I h
exposure to 0.01; CMean +s.d.; dSignificantly different from the
moderately melanised cell lines (P<0.01, by Student's t-test);
'Significantly different from the amelanotic cell lines (P<0.01, by
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Figure 2 Effects of 4-S-CAP upon thymidine incorporation in
B16-XID (a), B16-XIT (A), and B16-XIA (0) melanoma cell
lines. One x 105 cells were inoculated into Linbro multiwell tissue
culture trays and incubated for 48 h. Then, 4-S-CAP and
radiolabelled precursor were added simultaneously and were
incubated for 1 h. Values represent a mean of three experiments
performed with duplicate cultures; bars, s.d.
Table II Effects of 4-S-CAP on the incorporation of thymidine,
uridine, and leucine by the heavily melanised B16-XID melanoma
cells
Concentration % Inhibition
(figml-') Thymidine Uridine Leucine
1 8.1±3.4a 2.7± 1.0 2.1 ±0.8
10 92.1±3.0 8.4± 3.3 8.0± 1.2
100 94.2± 1.5 17.6±3.7 9.9±2.8
aMean±s.d.
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Figure 3 Effects of 4-S-CAP upon cell kinetics of the heavily
melanised B16-XID melanoma cells. Two x 105 cells were
inoculated into 60 mm Falcon Petri dishes and incubated for
48 h. Cells were incubated with different concentrations of 4-S-
CAP at 37°C for I h. After the treatment with 4-S-CAP, the
cultures were incubated at 37°C for 24 h. Aliquots of the cells
were treated with propidium iodide and analysed for cell cycle
DNA distribution as described in Materials and methods. 0, %
of G,-phase cells; 0, % of S-phase cells; and A, % of G2-M-
phase cells. Values represent a mean of three experiments per-
formed with duplicate cultures; bars, s.d.
treatment with 4-S-CAP on the completely amelanotic B16-
XIA melanoma cells showed no inhibition of thymidine
incorporation up to the concentration of 100pgml-'. For
the moderately melanised B16-XIT cells, 4-S-CAP showed an
intermediate inhibition of thymidine incorporation that fell
between the response seen in the B16-XID and B16-XIA
cells, and the percentage of inhibition at the concentration of
10 g ml-' was 63.6 ± 1.7%.
Next, the effects of 4-S-CAP on the radiolabelled thymi-
dine, uridine, and leucine incorporation by the heavily
melanised B16-XID melanoma cells were examined (Table
II). Compared to the inhibition of the thymidine incorpora-
tion seen, the inhibition of uridine and leucine was slight up
to the concentration of 100Itgml-'. Thus, the inhibition of
thymidine incorporation was found to be the most sensitive
index of the killing effect of 4-S-CAP, with lesser effects
observed upon uridine and leucine incorporation.
Inhibition ofcell cycle progression
After I h treatment with 4-S-CAP, the B16-XID cells percen-
tages during the G,, S, and G2-M phases were plotted for the
concentrations used (Figure 3). There was an accumulation
of S cells noted that depended upon the concentration of the
4-S-CAP, in association with a simultaneous decrease of G,
cells. The G2-M cells also were seen to accumulate slightly in
a larger concentration. The accumulation of S-phase cells,
depending upon the concentration, appears to be related to
the inhibition of the thymidine incorporation seen in the
B16-XID melanoma cells.
Discussion
Our results have demonstrated that 4-S-CAP has a remark-
ably potent killing activity for pigmented melanoma cells.
This killing effect was highly dependent upon the degrees of
melanin or tyrosinase synthesis in the melanoma cells, and it
had no killing effect on amelanotic melanoma cells and
nonmelanoma cells. Therefore, it may be that 4-S-CAP
becomes toxic to melanoma cells only after oxidation by
tyrosinase. Our previous report has indicated that 4-S-CAP is
a much better substrate for tyrosinase than L-tyrosine, and
that 4-S-CAP is oxidised to the corresponding o-quinone
form, which conjugates covalently with proteins through
cysteine residues (Ito et al., 1987). Thus, the killing effect of
4-S-CAP may be exerted on the pigmented melanoma cells
through its conversion to an o-quinone form and a subse-
quent scavenging action on sulfhydryl groups.
The killing activity of 4-S-CAP was found to be associated
with a profound inhibition of the thymidine incorporation, as
measured during exposure to the drug, with the greatest
inhibition seen in the heavily melanised melanoma cells.
Uridine and leucine incorporations were found to be largely
unaffected by 4-S-CAP. Thus, 4-S-CAP seems to exert its
cell-killing activity for melanoma cells primarily through the
inhibition of the DNA synthesis in comparison to RNA and
protein synthesis.
In the catecholic compounds, the inhibition of DNA poly-
merase has been postulated as being one site of action that
was based upon the ability of o-quinone forms to act as
sulfhydryl reagents (Wick et al., 1977; Wick, 1978). This
hypothesis is supported by the fact that o-quinones have a
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Figure 4 Possible mechanism of the killing effect of 4-S-CAP on
melanoma cells. R = - CH2CH2NH2.
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marked affinity for DNA polymerase alpha (Graham et al.,
1978b) and that L-dopa inhibits the activity of DNA poly-
merase alpha only in the presence of tyrosinase (Wick, 1980).
As a possible mechanism of 4-S-CAP action, therefore, it
may be that 4-S-CAP is oxidised by tyrosinase to the o-
quinone form via the catechol derivative and that some of
the quinones conjugate with sulfhydryl enzymes including
DNA polymerase alpha, thus triggered its killing activity
towards pigmented melanoma cells (Figure 4).
4-S-CAP is a stable compound in comparison to catecholic
compounds, and it can be activated by conversion to o-
quinone form only in the presence of tyrosinase. In a malig-
nant melanoma, the synthesis of melanin is highly elevated
because of a marked increase of tyrosinase activity. Thus,
our finding of this 4-S-CAP selective killing effect on
melanoma cells in which the melanin and tyrosinase synthesis
is highly active may favour its chemotherapeutic use for
treating malignant melanomas. Further, the synthesis of
tyrosinase and melanin, even in amelanotic melanoma cells,
can be enhanced by the administration of a melanocyte-
stimulating hormone (Pawelek, 1976; Siegrist, 1989). Thus,
4-S-CAP appears to provide a new, effective cytotoxic agent
for a rational chemotherapy that can ameliorate malignant
melanomas.
This work has been supported in part by Grants-in-Aid for Scientific
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